Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Oakmark Global Select Fund 2024 Q1 Investor Letter | Buyside Digest

Back to Fund Profile (Oakmark Global Select Fund)

Primary Source Intelligence • Q1 2024 Letter Analysis

Oakmark Global Select Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Oakmark Global Select Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+2.95%

Annualized+7.73%

Digest Analysis

Quick Take

"Oakmark Global Select underperformed in Q1 but maintains its value-focused approach, adding healthcare exposure through IQVIA and Centene while benefiting from Fiserv's payment processing leadership."

Executive Summary

The Oakmark Global Select Fund returned 2.95% in Q1 2024, underperforming the MSCI World Index's 8.88% return but maintaining its long-term outperformance since inception. The fund's core thesis centers on purchasing quality global businesses at discounts to intrinsic value. Fiserv was the top contributor, demonstrating strong execution in payment processing with peer-leading growth and margin expansion while trading at a discount to the S&P 500. Charter Communications detracted due to broadband subscriber declines, though managers expect competitive pressures to ease medium-term. The fund initiated three new positions: Reckitt Benckiser Group following a product liability lawsuit that created a valuation opportunity, IQVIA Holdings benefiting from biotech funding fears despite strong positioning in advanced therapeutics trends, and Centene capitalizing on government healthcare program outsourcing trends. Three positions were sold as they approached intrinsic value. The portfolio remains globally diversified with 60.4% in the US, 20.7% in Europe, 9.7% in the UK, and 8.2% in Asia, focusing on medium-term value realization opportunities.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The fund demonstrates moderate-high conviction through concentrated positioning with named holdings and specific position sizing (5-6% positions mentioned). Managers provide detailed thesis explanations for each investment and express willingness to hold through volatility, though the diversified global approach and hedged language around timing prevents higher scoring.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The managers express cautious optimism, acknowledging near-term challenges in broadband competition and biotech funding fears while maintaining confidence in medium-term prospects. They see selective opportunities created by temporary market dislocations but don't express broad market enthusiasm.

Risk Appetite

40%

DefensiveAggressive

Defensive (40%)

The fund demonstrates selective risk appetite by adding three new positions while maintaining existing holdings through volatility. They're willing to invest in companies facing temporary challenges like litigation (Reckitt) and sector headwinds (IQVIA), showing moderate risk tolerance.

Capital Deployment

15%

De-riskingDeploying

De-risking (15%)

The fund shows modest net deployment activity, adding three new positions while selling three others as they reached target valuations. This represents capital rotation rather than significant net deployment, with no cash level changes mentioned to indicate major portfolio shifts.

Forward Guidance

30%

CautiousExpansionary

Cautious (30%)

The managers indicate selective deployment bias, having added three new positions while selling three others at target valuations. They express willingness to invest in quality businesses at attractive valuations but maintain disciplined approach to capital allocation.

Language Signal

20%

BearishBullish

Bearish (20%)

Language is balanced with more opportunity-focused terms like 'attractive valuation,' 'compelling value,' and 'discount to intrinsic value' offset by risk acknowledgments including 'challenging,' 'competitive environment,' and 'legal liability risk.' Slightly more constructive than cautious overall.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

Managers acknowledge specific risks including broadband competition, government subsidy wind-downs, biotech funding concerns, and legal liability issues. However, these are presented as manageable, company-specific challenges rather than systemic threats, with solutions and timelines discussed for most concerns.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

The managers identify selective opportunities across multiple sectors and geographies, adding three new positions in different industries. They describe finding attractive valuations created by temporary market dislocations in biotech and consumer products, suggesting a reasonably rich opportunity set for selective investors.

Time Horizon

72%

Short-TermLong-Term

Decade+ (72%)

The fund demonstrates a multi-year investment horizon, explicitly discussing medium-term expectations for competitive forces to abate and businesses to realize value. Managers express willingness to hold through near-term volatility and focus on intrinsic value realization over 2-5 year periods rather than immediate catalysts.